✦ LIBER ✦

The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials

✍ Scribed by Wang, Xuan; Huang, Chun; Li, Man; Gu, Yanjun; Cui, Yanfen; Li, Yan

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comment on Wang et al.: The efficacy of

✍ Li, Jun; Yao, Yunfeng; Jing, Juehua 📂 Article 📅 2014 🏛 S. Karger AG 🌐 English ⚖ 74 KB

Bevacizumab plus paclitaxel versus bevac

✍ Lang, Istvan; Brodowicz, Thomas; Ryvo, Larisa; Kahan, Zsuzsanna; Greil, Richard; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 420 KB

Biomarker results from the AVADO phase 3

✍ Miles, D W; de Haas, S L; Dirix, L Y; Romieu, G; Chan, A; Pivot, X; Tomczak, P; 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 366 KB

Capecitabine plus paclitaxel versus epir

✍ Hans-Joachim Lück, Andreas Du Bois, Sibylle Loibl, Iris Schrader, Jens Huober, V 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 279 KB

5001 CIRG/TORI 010: first analysis of a

✍ M. Martin; S. Hurvitz; J. Kennedy; J. Forbes; H. Roché; T. Pinter; W. Eiermann; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Sunitinib Plus Paclitaxel Versus Bevaciz

✍ Nicholas J. Robert; Mansoor N. Saleh; Devchand Paul; Daniele Generali; Laurent G 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 798 KB